IASLC WCLC 2020: Phase 3 eXalt3 study shows significantly longer progression-free survival in patients with ALK lung cancer
Patients with non-small cell lung cancer (NSCLC) carrying anaplastic lymphoma kinase (ALK) gene alterations who…
Browsing: crizotinib
ASCO 2019: Entrectinib gets edge over crizotinib against ROS1 lung cancer
Crizotinib and entrectinib are both active against ROS1 non-small cell lung cancer. But which is…
ASCO 2019: 40-50 percent response rate for brigatinib after other next-gen ALK inhibitors
Crizotinib was the first drug licensed to treat ALK-positive non-small cell lung cancer (ALK NSCLC).…
Patients now living a median 6.8 years after stage IV ALK positive lung cancer diagnosis
According to the National Cancer Institute, patients diagnosed with non-small cell lung cancer (NSCLC) between…
CHMP announched positive opinion for brigatinib as treatment of ALK positive NSCLC in patients previously treated with crizotinib
The European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has adopted a positive…
Is your lung cancer really ROS1-negative?
Drugs like crizotinib are used to treat patients with ROS1-positive lung cancer. But which patients…
AACR 2018: Crizotinib yielded a high objective response rate for adult patients with ALK-positive inflammatory myofibroblastic tumour
Among patients with inoperable, advanced, or metastatic ALK-positive inflammatory myofibroblastic tumour, 50 percent were confirmed…